Cargando…
Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences
Cisplatin (CDDP) has been widely used as a chemotherapeutic agent for solid tumors. The most common side effect of CDDP is nephrotoxicity, and many efforts have been made in the laboratory and the clinic to employ candidate adjuvants to CDDP to minimize this adverse influence. Many synthetic and her...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454720/ https://www.ncbi.nlm.nih.gov/pubmed/28345324 http://dx.doi.org/10.22034/APJCP.2017.18.2.295 |
_version_ | 1783240887814324224 |
---|---|
author | Nematbakhsh, Mehdi Pezeshki, Zahra Jazi, Fatemeh Eshraghi Mazaheri, Bahar Moeini, Maryam Safari, Tahereh Azarkish, Fariba Moslemi, Fatemeh Maleki, Maryam Rezaei, Alireza Saberi, Shadan Dehghani, Aghdas Malek, Maryam Mansouri, Azam Ghasemi, Marzieh Zeinali, Farzaneh Zamani, Zohreh Navidi, Mitra Jilanchi, Sima Shirdavani, Soheyla Ashrafi, Farzaneh |
author_facet | Nematbakhsh, Mehdi Pezeshki, Zahra Jazi, Fatemeh Eshraghi Mazaheri, Bahar Moeini, Maryam Safari, Tahereh Azarkish, Fariba Moslemi, Fatemeh Maleki, Maryam Rezaei, Alireza Saberi, Shadan Dehghani, Aghdas Malek, Maryam Mansouri, Azam Ghasemi, Marzieh Zeinali, Farzaneh Zamani, Zohreh Navidi, Mitra Jilanchi, Sima Shirdavani, Soheyla Ashrafi, Farzaneh |
author_sort | Nematbakhsh, Mehdi |
collection | PubMed |
description | Cisplatin (CDDP) has been widely used as a chemotherapeutic agent for solid tumors. The most common side effect of CDDP is nephrotoxicity, and many efforts have been made in the laboratory and the clinic to employ candidate adjuvants to CDDP to minimize this adverse influence. Many synthetic and herbal antioxidants as well as trace elements have been investigated for this purpose in recent years and a variety of positive and negative results have been yielded. However, no definitive supplement has so far been proposed to prevent CDDP-induced nephrotoxicity; however, this condition is gender related and the sex hormone estrogen may protect the kidney against CDDP damage. In this review, the results of research related to the effect of different synthetic and herbal antioxidants supplements are presented and discussed with suggestions included for future work. |
format | Online Article Text |
id | pubmed-5454720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-54547202017-08-28 Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences Nematbakhsh, Mehdi Pezeshki, Zahra Jazi, Fatemeh Eshraghi Mazaheri, Bahar Moeini, Maryam Safari, Tahereh Azarkish, Fariba Moslemi, Fatemeh Maleki, Maryam Rezaei, Alireza Saberi, Shadan Dehghani, Aghdas Malek, Maryam Mansouri, Azam Ghasemi, Marzieh Zeinali, Farzaneh Zamani, Zohreh Navidi, Mitra Jilanchi, Sima Shirdavani, Soheyla Ashrafi, Farzaneh Asian Pac J Cancer Prev Review Cisplatin (CDDP) has been widely used as a chemotherapeutic agent for solid tumors. The most common side effect of CDDP is nephrotoxicity, and many efforts have been made in the laboratory and the clinic to employ candidate adjuvants to CDDP to minimize this adverse influence. Many synthetic and herbal antioxidants as well as trace elements have been investigated for this purpose in recent years and a variety of positive and negative results have been yielded. However, no definitive supplement has so far been proposed to prevent CDDP-induced nephrotoxicity; however, this condition is gender related and the sex hormone estrogen may protect the kidney against CDDP damage. In this review, the results of research related to the effect of different synthetic and herbal antioxidants supplements are presented and discussed with suggestions included for future work. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5454720/ /pubmed/28345324 http://dx.doi.org/10.22034/APJCP.2017.18.2.295 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Review Nematbakhsh, Mehdi Pezeshki, Zahra Jazi, Fatemeh Eshraghi Mazaheri, Bahar Moeini, Maryam Safari, Tahereh Azarkish, Fariba Moslemi, Fatemeh Maleki, Maryam Rezaei, Alireza Saberi, Shadan Dehghani, Aghdas Malek, Maryam Mansouri, Azam Ghasemi, Marzieh Zeinali, Farzaneh Zamani, Zohreh Navidi, Mitra Jilanchi, Sima Shirdavani, Soheyla Ashrafi, Farzaneh Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences |
title | Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences |
title_full | Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences |
title_fullStr | Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences |
title_full_unstemmed | Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences |
title_short | Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences |
title_sort | cisplatin-induced nephrotoxicity; protective supplements and gender differences |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454720/ https://www.ncbi.nlm.nih.gov/pubmed/28345324 http://dx.doi.org/10.22034/APJCP.2017.18.2.295 |
work_keys_str_mv | AT nematbakhshmehdi cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT pezeshkizahra cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT jazifatemeheshraghi cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT mazaheribahar cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT moeinimaryam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT safaritahereh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT azarkishfariba cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT moslemifatemeh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT malekimaryam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT rezaeialireza cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT saberishadan cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT dehghaniaghdas cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT malekmaryam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT mansouriazam cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT ghasemimarzieh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT zeinalifarzaneh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT zamanizohreh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT navidimitra cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT jilanchisima cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT shirdavanisoheyla cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences AT ashrafifarzaneh cisplatininducednephrotoxicityprotectivesupplementsandgenderdifferences |